Last updated: March 3, 2026
What is the Drug Identified by NDC 16714-0937?
NDC 16714-0937 corresponds to Tecentriq (atezolizumab), an immune checkpoint inhibitor developed by Genentech, a Roche subsidiary. Approved by the FDA in May 2016, it treats certain types of metastatic urothelial carcinoma and non-small cell lung cancer (NSCLC).
Market Overview and Demand Drivers
Indications and Market Penetration
- Primary indications: Urothelial carcinoma, NSCLC, triple-negative breast cancer, small cell lung cancer.
- Market adoption: Established as a first- and second-line therapy for several indications; competitive landscape includes Keytruda (pembrolizumab) and Opdivo (nivolumab).
Market Size and Trends
- Global oncology immunotherapy market: Valued at ~$35 billion in 2022 with a CAGR of 10% through 2028 (Fortune Business Insights).
- Technical factors: Increasing prevalence of lung and bladder cancers; approval expansion into additional indications increases potential patient pool.
- Competitive landscape: Several PD-1/PD-L1 inhibitors with comparable efficacy, impacting Tecentriq’s market share.
Pricing and Usage Trends
- Pricing: Approximate wholesale acquisition cost (WAC) per 1200 mg dose is $12,500.
- Treatment cycles: Administered every three weeks, with typical course durations of 6-12 cycles.
- Revenue impact: Top-line sales depend on volume, traditionally driven by commercial coverage, institutional adoption, and prescribing habits.
Pricing Analysis
Current Pricing Structure
| Parameter |
Details |
| Dose size |
1200 mg |
| Price per dose |
$12,500 |
| Treatment frequency |
Every 3 weeks |
| Estimated annual cost |
~$250,000 (for a typical year of treatment) |
Price Trends (2016–2023)
| Year |
Approximate WAC Price per Dose |
Notes |
| 2016 |
$12,000 |
Initial launch price |
| 2018 |
$12,500 |
Stable, slight increase |
| 2020 |
$12,650 |
Post-expansion into NSCLC |
| 2022 |
$12,500 |
Stable, competitive pressures |
| 2023 |
$12,500 |
Maintains market position |
Price Projection Factors
- Patent exclusivity: Patents are valid til 2028–2030; biosimilar entry anticipated thereafter.
- Market competition: Price competition from biosimilars and other immunotherapies could drive prices downward post-2028.
- Volume effects: Increasing indications and expanded access can offset per-dose price pressure through higher total revenue.
- Healthcare policies: Price negotiations, reimbursement policies, and formulary placements influence net pricing.
Revenue and Market Share Forecasts
Volume Assumptions (Next 5 Years)
- Global annual patient volume: Estimated at 20,000–25,000 in 2023.
- Growth rate: Compound annual growth rate (CAGR) of 8%, driven by new indications.
- Market penetration: Expected to reach 85% of eligible patients in primary markets (US, Europe).
Revenue Projections
| Year |
Estimated Patient Volume |
Average Price per Course |
Projected Revenue (USD) billions |
| 2023 |
20,000 |
$250,000 |
$5.0 |
| 2024 |
21,600 |
$250,000 |
$5.4 |
| 2025 |
23,300 |
$250,000 |
$5.8 |
| 2026 |
25,000 |
$250,000 |
$6.3 |
| 2027 |
26,900 |
$250,000 |
$6.7 |
Note: These figures assume stable pricing and no significant biosimilar competition initially.
Implications of Biosimilar Entry
Biosimilar development for atezolizumab is progressing, with key candidates in late-stage trials. Entry could:
- Drive price reductions by 20-40% post-2028.
- Reduce average treatment costs, impacting revenue projections.
- Increase patient access, expanding total market size.
Expected biosimilar approval and commercialization could occur between 2028 and 2030.
Policy and Regulatory Impact
- Reimbursement negotiations: CMS and international bodies influence net prices.
- Pricing reforms: Emerging policies targeting drug pricing transparency and cost controls may impact future topline sales.
Key Takeaways
- Tecentriq’s current market position is stable, with steady pricing at ~$12,500 per 1200 mg dose.
- Revenue growth depends largely on volume expansion and indication approval.
- Biosimilar competition expected post-2028 will likely pressure prices downward.
- The primary markets (US, EU) maintain the highest revenue potential due to higher adoption rates.
- Future price trends will be shaped by regulatory, competitive, and policy developments.
FAQs
Q1: What is the main driver of Tecentriq’s revenue growth?
Increasing patient volume due to expanded indications and market penetration.
Q2: How will biosimilar entry affect Tecentriq’s pricing?
Biosimilars are expected to reduce prices by 20-40%, impacting revenue.
Q3: Are there significant regional price differences for Tecentriq?
Yes, US prices are higher, reflecting different reimbursement systems, while EU prices are regulated and generally lower.
Q4: What patient numbers are projected for Tecentriq in 2025?
Approximately 23,300 patients annually, assuming a CAGR of 8%.
Q5: Will Tecentriq’s pricing adjust for new indications?
Pricing may remain stable or slightly decrease due to competitive pressures, but expanded indications increase total market volume.
References
- Fortune Business Insights. (2022). Oncology Immunotherapy Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/industry-reports/oncology-immunotherapy-market-102165
- U.S. Food and Drug Administration. (2016). FDA approves atezolizumab for bladder cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-atezolizumab-bladder-cancer
- IQVIA. (2023). Global Oncology Market Data.
- BioCentury. (2022). Biosimilar pipeline for PD-L1 inhibitors.
- Centers for Medicare & Medicaid Services. (2023). Pharmaceutical pricing policies overview.
Note: Data projections are estimates based on current market conditions, historical trends, and known regulatory and competitive factors.
